Miriam B. Vos, Joel E. Lavine – 6 February 2013 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in adults and children. A number of genetic and environmental factors are known to predispose individuals to NAFLD. Certain dietary sugars, particularly fructose, are suspected to contribute to the development of NAFLD and its progression. The increasing quantity of fructose in the diet comes from sugar additives (most commonly sucrose and high fructose corn syrup) in beverages and processed foods.

Han Han, Dan Sun, Wenjuan Li, Hongxing Shen, Yahui Zhu, Chen Li, Yuxing Chen, Longfeng Lu, Wenhua Li, Jinxiang Zhang, Yuan Tian, Youjun Li – 6 February 2013 – c‐Myc (Myc) plays an important role in normal liver development and tumorigenesis. We show here that Myc is pathologically activated in and essential for promoting human hepatocellular carcinoma (HCC). Myc induces HCC through a novel, microRNA (miRNA)‐mediated feedback loop comprised of miR‐148a‐5p, miR‐363‐3p, and ubiquitin‐specific protease 28 (USP28).

Xi‐Dai Long, Jin‐Guang Yao, Zhi Zeng, Yun Ma, Xiao‐Ying Huang, Zhong‐Hua Wei, Min Liu, Jian‐Jun Zhang, Feng Xue, Bo Zhai, Qiang Xia – 6 February 2013 – X‐ray repair complementing group 4 (XRCC4) is very important in maintaining overall genome stability and may play an important role in carcinogenesis. We aimed to investigate the role of polymorphisms in the coding region of this gene in hepatocellular carcinoma (HCC) caused by aflatoxin B1 (AFB1).

Susana Seijo, Aurelie Plessier, Jildou Hoekstra, Alessandra Dell'Era, Dalvinder Mandair, Kinan Rifai, Jonel Trebicka, Isabelle Morard, Luc Lasser, Juan G. Abraldes, Sarwa Darwish Murad, Jörg Heller, Antoine Hadengue, Massimo Primignani, Elwyn Elias, Harry L.A. Janssen, Dominique C. Valla, Juan‐Carlos Garcia‐Pagan, for the European Network for Vascular Disorders of the Liver – 6 February 2013 – Budd‐Chiari syndrome (BCS) is a rare, life‐threatening disease caused by obstruction of hepatic venous outflow.

Susana Seijo, Aurelie Plessier, Jildou Hoekstra, Alessandra Dell'Era, Dalvinder Mandair, Kinan Rifai, Jonel Trebicka, Isabelle Morard, Luc Lasser, Juan G. Abraldes, Sarwa Darwish Murad, Jörg Heller, Antoine Hadengue, Massimo Primignani, Elwyn Elias, Harry L.A. Janssen, Dominique C. Valla, Juan‐Carlos Garcia‐Pagan, for the European Network for Vascular Disorders of the Liver – 6 February 2013 – Budd‐Chiari syndrome (BCS) is a rare, life‐threatening disease caused by obstruction of hepatic venous outflow.

Juan Pablo Arab, Luis Meneses, Rosa M. Pérez, Marco Arrese, Carlos Benítez – 6 February 2013

Alphonse E. Sirica – 6 February 2013

Johann Guillemot, Maryssa Canuel, Rachid Essalmani, Annik Prat, Nabil G. Seidah – 6 February 2013 – The first seven members of the proprotein convertase (PC) family activate protein precursors by cleavage after basic residues. While PC7 has no known specific substrates, it shows redundancy with other PCs. A genome‐wide association study suggested that circulating levels of shed human transferrin receptor 1 (hTfR1) are regulated by PC7. We thus examined whether hTfR1 constitutes a specific substrate for PC7.

Yao‐Chun Hsu, Hsiu J. Ho, Ming‐Shiang Wu, Jaw‐Town Lin, Chun‐Ying Wu – 6 February 2013 – Hepatocellular carcinoma (HCC) frequently recurs after surgical resection. This population‐based research aimed to investigate the association between postoperative antiviral treatment and risk of recurrent HCC in patients with hepatitis C virus (HCV) infection. By analyzing the Taiwan National Health Insurance Research Database, we initially screened a total of 100,938 patients diagnosed with HCC for the first time between October 2003 and December 2010.

Grace Lai‐Hung Wong, Henry Lik‐Yuen Chan, Christy Wing‐Hin Mak, Stanley King‐Yeung Lee, Zoe Man‐Yi Ip, Andrew Ting‐Ho Lam, Henry Wing‐Hang Iu, Joyce May‐Sum Leung, Jennifer Wing‐Yan Lai, Angeline Oi‐Shan Lo, Hoi‐Yun Chan, Vincent Wai‐Sun Wong – 6 February 2013 – Entecavir is a potent antiviral agent with high genetic barrier to resistance, hence it is currently recommended as first‐line antiviral therapy for chronic hepatitis B (CHB). The aim of this study was to investigate the efficacy of entecavir on clinical outcomes and deaths.